Clinical trials: Metastatic Cancer, open to volunteers
Local Advanced or Metastatic NSCLC
Garsorasib In KRAS G12C Mutant Locally Advanced and Metastatic NSCLC
This study is aimed to evaluate the efficacy and safety of the Garsorasib combination therapy in KRAS G12C mutant locally advanced and metastatic NSCLC
- Trial name
- NCT07294261
- Testing
- Garsorasib, Benmelstobart, Anlotinib, Benmelstobart, Anlotinib, Garsorasib, Cetuximab Beta Injection
- Where
- China
- Volunteers
- 69 people
- Sponsor
- Sun Yat-sen University
Immune-Mediated Cholestasis
Comparing UDCA and Corticosteroids in Immunotherapy Induced Cholestatic Hepatitis
The clinical trial aims to compare the effectiveness of ursodeoxycholic acid (UDCA) to corticosteroids in treating cholestatic hepatitis induced by immune checkpoint inhibitors (ICIs) over a 21-day period.
- Trial name
- CHILURSO (NCT07378761)
- Testing
- UDCA (Ursodeoxycholic acid), Corticosteroids (Reference Treatment)
- Where
- 6 sites in France
- Volunteers
- 94 people
- Sponsor
- University Hospital, Montpellier
Uveal Melanoma, Metastatic
Tebentafusp and Roginolisib in Uveal Melanoma to Prolong T-cell Homeostasis
This is a combination study of Tebentafusp and the PI3Kdelta inhibitor, Roginolisib
- Trial name
- TRIUMPH (NCT07203391)
- Testing
- roginolisib
- Where
- 2 sites in Australia
- Volunteers
- 8 people
- Sponsor
- St Vincent's Hospital, Sydney
Localized Prostate Carcinoma, Oligometastatic Prostate Carcinoma
Accuracy of 18F-rhPSMA-7.3 PET/ MRI for Prediction of Lymph Node Metastasis in Localized High-Risk Prostate Cancer
This clinical trial evaluates the use of an imaging scan (18F-rhPSMA-7.3 positron emission tomography [PET]/magnetic resonance imaging [MRI]) for identifying patients who are at risk of having their disease spread to the lymph…
- Conditions
- Localized Prostate Carcinoma, Oligometastatic Prostate Carcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8
- Trial name
- NCT06389786
- Testing
- Bilateral Pelvic Lymph Node Dissection, Biospecimen Collection, Bone Scan
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Mayo Clinic
Breast Cancer
A Study on Predicting the Risk of Distant Metastasis in Breast Cancer Using AI-Generated Spatial Pathological Maps
The goal of this observational study is to develop and validate an artificial intelligence (AI) model for predicting the risk of distant metastasis in patients with primary breast cancer.
- Trial name
- ARGUS project (NCT07244094)
- Testing
- Diagnostic Test: AI-Based Spatial Pathomic Analysis
- Where
- 4 sites in China
- Volunteers
- 400 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Metastatic Castration-resistant Prostate Cancer
Dose-Escalation Study of Cabozantinib in Combination With Lutetium-177 (177Lu)-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer
This is an open-label, phase 1b dose-escalation study of cabozantinib in combination with 177Lu-PSMA-617 in subjects with mCRPC.
- Trial name
- CaboLu (NCT05613894)
- Testing
- Cabozantinib
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- University of Utah
EGFR, NSCLC (Advanced Non-small Cell Lung Cancer)
Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation
This study is a randomized, open, multicenter phase III clinical study, which aims to evaluate the efficacy and safety of firmonertinib mesylate compared with platinum based chemotherapy for patients with locally advanced or…
- Trial name
- NCT06956001
- Testing
- Firmonertinib Mesilate Tablets, Pemetrexed Disodium for Injection, Cisplatin for injection
- Where
- 2 sites in China
- Volunteers
- 300 people
- Sponsor
- Allist Pharmaceuticals, Inc.
Pancreatic Cancer Metastatic
Adebrelimab Infusion Plus Standard Care for Pancreatic Cancer With Pleural or Peritoneal Effusions
1. Study: A Clinical Study of Intra-cavity Adebrelimab Combined with Best Supportive Care for Pancreatic Cancer Patients with Pleural or Peritoneal Effusion (Malignant Ascites) 2.
- Trial name
- NCT07230301
- Testing
- Adebrelimab (PD-L1 inhibitor)
- Volunteers
- 20 people
- Sponsor
- Sizhen Wang
Breast Cancer, Metastatic Breast Cancer
Mapping the Enhanced Landscape of Advanced Breast Cancer fOr DYnamic Treatment Approaches
MELODY is a prospective, single-arm phase II study introducing routine liquid-biopsy next-generation sequencing for patients with advanced or unresectable breast cancer in Ireland.
- Conditions
- Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast Cancer (LABC)
- Trial name
- MELODY (NCT07893730)
- Testing
- Liquid biopsy next generation sequencing
- Volunteers
- 50 people
- Sponsor
- University College Cork
Malignant Pleural Effusion, Malignant Mesothelioma
Fast TILs to Treat Metastatic Cancer Patients With Pleural Disease
This research study aims to evaluate the safety and effectiveness of a novel immunotherapy, Fast TIL, an Adoptive Cellular Therapeutic (ACT), to fight cancer that has spread to the pleura or pleural mesothelioma.
- Conditions
- Malignant Pleural Effusion, Malignant Mesothelioma, Pleural Effusion, Malignant, Metastasis to Pleura
- Trial name
- (RIOT 4A) (NCT07192900)
- Testing
- locally manufactured adoptive cellular therapy (ACT) product, Interleukin-2
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- David Bartlett, MD
Locally Advanced Pancreatic Cancer, Metastatic Pancreatic Cancer
mFOLFIRINOX Plus Anlotinib and Sintilimab for Advanced Pancreatic Cancer
This study is a prospective, single-arm, multicenter, phase Ib/II clinical trial that treats previously untreated patients with locally advanced or metastatic pancreatic cancer using mFOLFIRINOX in combination with anlotinib and…
- Trial name
- NCT06761027
- Testing
- Anlotinib combined with Sintilimab
- Where
- 4 sites in China
- Volunteers
- 29 people
- Sponsor
- Fujian Provincial Hospital
Metastatic Breast Cancer With HER2 Positive
SHR-A1811 Combine With Pyrotinib for Locally Advanced/Metastatic HER2 Positive Breast Cancer
The goal of this clinical trial is to learn if SHR-A1811 combine with Pyrotinib is safe and tolerable for patients with HER2 positive breast cancer. It will also learn about the anti-tumor efficacy of this combination therapy.
- Trial name
- NCT07132242
- Testing
- SHR-A1811 4.0mg/kg, Pyrotinib 240mg, SHR-A1811 4.8mg/kg
- Volunteers
- 84 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Gastric Cancer (Diagnosis), Gastric Cancer (GC)
A Clinical Study of Iparomlimab and Tuvonralimab Combined With SOX Following Heterogeneous Radiotherapy as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Gastric or Gastroesophageal Junction Adenocarcinoma
This study is a domestic, multicenter, single-arm clinical trial designed to evaluate the efficacy and safety of heterogeneous radiotherapy (high and low dose) sequenced with iparomlimab and tuvonralimab plus SOX as a first-line…
- Conditions
- Gastric Cancer (Diagnosis), Gastric Cancer (GC), Gastroesophageal Junction Adenocarcinoma
- Trial name
- NCT07502027
- Testing
- Iparomlimab and Tuvonralimab (QL1706)
- Volunteers
- 55 people
- Sponsor
- Huazhong University of Science and Technology
Triple-negative Breast Cancer
A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast Cancer
This phase II study is a clinical study to explore the efficacy and safety of BL-B01D1 combined with PD-1 monoclonal antibody in patients with unresectable locally advanced or recurrent metastatic triple-negative breast cancer.
- Trial name
- NCT06471205
- Testing
- BL-B01D1, PD-1 Monoclonal Antibody
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Metastatic Breast Cancer
Minimally Interventional Study on Prevalence of Emerging ESR1 Mutations in Liquid Biopsy in Three Cohorts of Patients With Breast Cancer in Comparison With Patient's Baseline ESR1 Mutation Status as Defined by Tissue Profiling.
Minimally interventional study on prevalence of emerging ESR1 mutations in liquid biopsy in three cohorts of patients with breast cancer (with and without prior therapies in metastatic setting, and during first-line aromatase…
- Trial name
- Pangeia-2 (NCT06417801)
- Where
- 6 sites in Brazil
- Volunteers
- 170 people
- Sponsor
- AstraZeneca
Colorectal Cancer Metastatic, Microsatellite Stable Colorectal Carcinoma
Sequential Immunochemotherapy Treatment with Pembrolizumab Plus Dendritic Cell (DC) Vaccine Followed by Trifluridine/Tipiracil Plus Bevacizumab in Refractory Mismatch-repair-proficient (pMMR) or Microsatellite-stable (MSS) Metastatic Colorectal Cancer
Single-arm, open-label, multicenter phase 2 clinical trial evaluating the clinical and the immunological activity of an innovative strategy with an induction combo immunotherapy (Pembrolizumab plus DC Vaccine) followed by a…
- Conditions
- Colorectal Cancer Metastatic, Microsatellite Stable Colorectal Carcinoma, Refractory Mismatch-repair-proficient (pMMR) Metastatic Colorectal Cancer
- Trial name
- CombiCoR-Vax (NCT06522919)
- Testing
- Autologous Dendritic Cell (DC) Vaccine
- Where
- 2 sites in Italy
- Volunteers
- 36 people
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Metastatic Breast Cancer, Stage IV Breast Cancer AJCC V7
Enhancing Access to Supportive Services for Women of Color With Metastatic Breast Cancer
Black and Latina women experience disparities in supportive and palliative care access and outcomes. The goal of the proposed pilot study is to evaluate the feasibility and acceptability of a community navigator delivered…
- Trial name
- ACCESS (NCT06405828)
- Testing
- ACCESS Supportive Care, Phone sessions
- Where
- United States
- Volunteers
- 67 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Colorectal Cancer (CRC), Capecitabine
First-line Treatment of MCapOX + Cetuximab Vs. MFOLFOX6 + Cetuximab for RAS/BRAF Wild-type, MSS, Unresectable Left-Sided MCRC: a Multicenter, Randomized, Controlled, Phase III Study
This multicenter, randomized, controlled, phase III study is conducted to evaluate the efficacy and safety of first line mCapOX plus Cetuximab versus mFOLFOX6 plus Cetuximab for RAS/BRAF wild-type, MSS, Unresectable Left-Sided…
- Conditions
- Colorectal Cancer (CRC), Capecitabine, Cetuximab
- Trial name
- CAPCET-III (NCT06616259)
- Testing
- mCapOX plus Cetuximab, mFOLFOX6 plus Cetuximab
- Where
- China
- Volunteers
- 452 people
- Sponsor
- Meng Qiu
Colon Cancer Liver Metastasis, Colon Cancer
Biopsy After Radioembolization to Identify Changes in Tumor Cells From the Radiation
The purpose of this study is to study the way radioembolization works by collecting biopsy samples of participants' tumors after the procedure.
- Conditions
- Colon Cancer Liver Metastasis, Colon Cancer, Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
- Trial name
- NCT04668872
- Testing
- Y90 TARE, PET/CT, PET/MRI
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Solid Tumor, Adult, Metastatic Solid Tumor
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
This first-in-human, open-label, multicenter, multi-arm dose-escalation study is designed to evaluate the safety, PK, and PD of ADU-1805, an anti- SIRPα monoclonal antibody, as monotherapy and in combination with pembrolizumab…
- Conditions
- Solid Tumor, Adult, Metastatic Solid Tumor, Refractory Cancer, CRC, Colorectal Cancer
- Trial name
- NCT05856981
- Testing
- ADU-1805, Pembrolizumab
- Where
- 11 sites in United States, Belgium and 1 more
- Volunteers
- 130 people
- Sponsor
- Sairopa B.V.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.